Adapthealth Corp (AHCO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Adapthealth Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 10.80 $ — 45% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 38.4%
- Exp. sales growth 3Y > 5% 7.0%
- EBIT growth 10Y > 5% 62.8%
- Exp. EBIT growth 3Y > 5% 7.0%
- Net debt < 4x EBIT 9.6x
- EBIT positive, 10Y straight 7
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% –
- ROCE > 15% 5.2%
- Expected return > 10% 23.1%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 3.0% failed
- More than 10% revenue growth is expected for the coming year 6.5% failed
- Share count grows by less than 3% a year -0.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 6.3% failed
- Gross margin at 40% or higher and without meaningful erosion 17.5% failed
- Goodwill from acquisitions does not grow faster than revenue 58.9% passed
- Net debt below twice EBITDA 3.6 x EBITDA failed
- Operating cash flow covers the profits of the last three years 2,284 m passed
- Return on capital at 15% or higher, or up versus two years ago 5.2% passed
- Insiders hold at least 10% or are net buyers 8.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 30.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.89 | 0.69 – 1.11 | 3,486 | 64.3% | 5 |
| 12/31/2027 | 1.17 | 0.82 – 1.49 | 3,716 | 30.7% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.37 | – | 857 | -42.00 | 5.90 | 150 | 73 |
| 2025: Q1 | -0.05 | – | 581 | -2.30 | -1.20 | 96 | 0 |
| 2025: Q2 | 0.11 | -25.10 | 592 | -0.50 | 2.50 | 162 | 73 |
| 2025: Q3 | 0.18 | 6.70 | 603 | 0.90 | 4.10 | 161 | 67 |
| 2025: Q4 | -0.76 | -306.10 | 846 | -1.20 | -12.10 | 183 | 79 |
| 2026: Q1 | -0.12 | – | 820 | 41.20 | -2.00 | 94 | -28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 174 | 2 | -4 | -0.12 | 30 | – | – |
| 2017 | 193 | 0 | 0 | 0.00 | 46 | 0 | 0 |
| 2018 | 345 | -1 | 2 | 0.07 | 68 | 246 | 254 |
| 2019 | 530 | 29 | -21 | -0.95 | 60 | 15 | 228 |
| 2020 | 1,056 | 71 | -162 | -3.08 | 196 | 355 | 1,813 |
| 2021 | 2,455 | 226 | 156 | 1.17 | 276 | 2,062 | 5,250 |
| 2022 | 2,971 | 190 | 69 | 0.50 | 374 | 2,151 | 5,220 |
| 2023 | 3,200 | -598 | -679 | -5.05 | 481 | 1,458 | 4,509 |
| 2024 | 3,261 | 264 | 90 | 0.67 | 542 | 1,571 | 4,487 |
| 2025 | 3,245 | 186 | -71 | -0.52 | 602 | 1,519 | 4,317 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
AdaptHealth Corp. vertreibt zusammen mit seinen Tochtergesellschaften medizinische Heimausstattung (HME), medizinische Verbrauchsmaterialien sowie häusliche und verwandte Dienstleistungen in den USA.
| Employees | 10,900 |
|---|---|
| Headquarters | Conshohocken, PA |
| Address | 555 East North Lane, 19428 Conshohocken, United States |
| Phone | 610 424 4515 |
| Website | adapthealth.com |
| IPO Date | 24. May 2018 |
| ISIN | US00653Q1022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Suzanne M. Foster M.P.H. | CEO & Director | 1970 |
| Jason A. Clemens C.F.A. | Chief Financial Officer | 1979 |
| Albert A. Prast | CTO & Chief Innovation Officer | 1960 |
| Russell E. Schuster III | Chief Commercial Officer | 1977 |
| Daniel McFadden | Chief Operations Officer | 1971 |
| Christine E. Archbold | Chief Accounting Officer | 1974 |
| Nalin Narayanam | Chief Information Officer | – |
| Wendy Russalesi | Chief Compliance Officer | – |
| Richard W. Rew II | Chief Legal Officer, General Counsel & Secretary | 1968 |
| Kelly Morgan | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.